SMARCE1 is altered in 0.62% of all cancers with esophageal adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, melanoma, and colon adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in SMARCE1 are SMARCE1 Amplification (0.40%), SMARCE1 A308T (0.03%), SMARCE1 D375N (0.02%), SMARCE1 E330K (0.02%), and SMARCE1 Fusion (0.02%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.